# TB-500 reported effects and safety — what the record shows > TB-500 reported effects, community signals, and safety cautions: what research-use communities describe, what animal studies show, and what the honest risk record looks like for the synthetic Thymosin Beta-4 fragment. The effects attributed to TB-500 in research-use communities, alongside the honest safety cautions the published and regulatory record supports. ## The short version TB-500 is a seven-amino-acid fragment of a protein your body makes naturally. Animal studies show the parent protein — full-length Thymosin Beta-4 — can speed tissue repair, calm inflammation, and support cardiac and neural recovery. Whether the shorter TB-500 fragment does the same things in a human body is simply not documented in controlled clinical research. No registered human trial of TB-500 itself has ever been completed. What follows is two separate layers of information: first, what people in research-use communities say they experience (anecdotal, not clinical evidence); second, what the published and regulatory record identifies as genuine cautions. Neither layer constitutes medical advice. ## What people report **The following signals are anecdotal, not clinical evidence.** They come from peptide-user forums, wellness-clinic write-ups, and research-supplier review pages — personal accounts from people who have used TB-500 in an uncontrolled, non-research setting. They are reported here because they are part of the honest record, not because they are verified by clinical study. **Benefits most often mentioned:** - **Faster recovery from tendon, ligament, and muscle injuries** (very commonly reported). This is the main reason people in research-use communities reach for TB-500. They describe nagging soft-tissue injuries feeling better and returning to activity sooner than expected. Timelines vary widely and controlled conditions are absent. - **Less joint pain and stiffness, better range of motion** (frequently reported). People with general wear-and-tear stiffness most often mention this, typically over a few weeks. No controlled human trial underlies these joint-comfort reports. - **Improved overall flexibility and mobility** (frequently reported). Overlaps with the joint reports; people typically notice it around weeks three to four. - **Feeling of reduced inflammation or calmed-down soreness** (occasionally reported). A softer, vaguer signal than the injury-recovery reports — no human study confirms an anti-inflammatory benefit from the TB-500 fragment specifically. - **Better wound and skin healing** (occasionally reported). Some people mention cuts or surgical sites seeming to close more quickly, consistent with what animal studies show for the parent protein. - **Hair regrowth or thicker hair** (rarely reported). A minor and inconsistent signal, difficult to separate from other concurrent interventions. **Adverse effects most often mentioned:** - **Injection-site redness, swelling, or aching** (very commonly reported). The most common complaint — a small pink, sore spot that typically resolves within a day or two. Not unique to TB-500. - **Temporary tiredness or lethargy** (frequently reported). Many users describe unusual fatigue for a day or two, especially early on, that fades as use continues. - **Head rush, lightheadedness, or headache** (occasionally reported). Brief and self-resolving; less common than tiredness. - **Brief flu-like feeling** (occasionally reported). Mild and short-lived; described as the body reacting to a new peptide. - **Nausea** (rarely reported). Mild; more common at larger amounts. - **Heightened awareness of an existing injury** (rarely reported). Some users report an old injury feeling more active in the first one to two weeks. - **Temporary low mood or mood changes** (rarely reported). Vague and uncommon; no clinical evidence ties TB-500 to mood effects. ## Safety and cautions The following cautions reflect what the published and regulatory record supports. They are organized from the most firmly evidenced to the most theoretical. **Human safety is essentially unstudied.** No completed controlled human trial of the TB-500 heptapeptide exists for any indication. A 2026 Sports Medicine review of unapproved peptides concluded that compounds like TB-500 show promise in animal models but carry scarce human safety data, potential for serious harm, and operate largely outside regulatory oversight [26]. The only published human safety data are for full-length recombinant Thymosin Beta-4 — a different molecule — in a Phase I intravenous study in healthy volunteers [12]. **Theoretical cancer and tumor-growth concern (preclinical signal).** The parent protein Thymosin Beta-4 is overexpressed in several cancers — including pancreatic cancer cells, where it stimulated proinflammatory cytokine secretion [28] — and has been linked to tumor spread and to the growth of new blood vessels that feed tumors [27]. The same pro-migration, pro-angiogenic properties that may help tissue repair could, in principle, support tumor progression. This signal has not been measured for TB-500 in humans, but people with a current or past cancer, or strong family cancer risk, are the group most often identified as warranting precaution. **Banned in competitive sport.** The World Anti-Doping Agency prohibits TB-500 under its peptide and growth-factor categories. Anti-doping laboratories have validated methods to detect TB-500 and its breakdown products in both equine and human biological matrices [29]. A positive test can end an athlete's eligibility regardless of any claimed recovery benefit. **Animal evidence includes honest negative results.** A long-term animal study gave dystrophin-deficient mice thymosin beta-4 twice weekly for six months and found more regenerating muscle fibers — but no improvement in muscle strength, cardiac function, or fibrosis [30]. More apparent regeneration did not translate into better functional outcomes, which is a caution against assuming felt improvements reflect real structural repair. **TB-500 is a fragment, not the full parent protein.** Almost all encouraging efficacy research used full-length Thymosin Beta-4. TB-500 carries only the short actin-binding region (residues 17 to 23) and lacks the structural features linked to the parent protein's highest-affinity interactions [31]. Analytical work characterizing TB-500 preparations confirms it as a distinct species from the parent protein [29]. Applying the parent protein's results to the fragment is an extrapolation that has not been confirmed in controlled research. **Research-grade product quality is not guaranteed.** Material sold as TB-500 for research is not manufactured to medicine-grade standards; identity, purity, and exact sequence vary between suppliers. A 2023 analytical study characterizing TB500/TB1000 preparations for doping control underscores how much composition matters for any interpretation of results [32]. **Theoretical cautions in specific populations.** Because the parent protein influences blood-vessel formation and platelet activity at injury sites, people with clotting disorders or those near surgery face uncertain effects — a mechanism-based inference, not a measured finding. Pregnant or breastfeeding individuals and anyone still developing are a precautionary group for the same reason. There are no human safety data in any of these populations. --- An independent editorial survey of the published regulatory and research record — not a clinic, not a vendor, not legal counsel.